The case for & against
Bull & Bear analysis
Bearish
AIM Immunotech Inc. (NYSE: AIM) is a biotechnology company specializing in developing innovative therapeutics for oncology and chronic conditions, notably long COVID. The firm is actively advancing its lead candidate, Ampligen (rintatolimod), which is under investigation for various cancers and post-viral fatigue. AIM is strategically collaborating with major pharmaceutical partners like AstraZeneca to leverage their expertise and resources in clinical trials, positioning itself as a significant player in the biopharmaceutical field focused on unmet medical needs.
Bull says
- ↑Ampligen delivered 45% objective response rate in ovarian cancer Phase II.
- ↑Collaborations with AstraZeneca and Merck enhance trial design and credibility.
- ↑Patent portfolio expanded to cover endometriosis and long COVID therapies.
- ↑Production cost per Ampligen batch cut from $400K to $200K, boosting margins.
- ↑$10.1M cash as of Q2 2024 supports ongoing trials and operations.
- ↑Strong analyst revisions and liquidity factors signal growing investor interest.
Bear says
- ↓Only $4M cash as of Q4 2024 heightens risk of funding shortfalls.
- ↓FDA approval delays on AMP270 trial could push key milestones back.
- ↓Negative profitability margins and rising operational costs threaten earnings.
- ↓Short interest at 11% reflects market skepticism about clinical success.
- ↓Competition from Moderna and Clovis Oncology intensifies market pressures.
- ↓Negative earnings yield and poor momentum factors indicate valuation risk.
Earnings Call · Q1 2024 · Mgmt. Guidance
Updated 09-10-2026bullish
Transcript signals
Bull points
- The FDA has granted our Type D meeting request regarding the AMP270 study in locally advanced pancreas cancer, and according to their proposed timeline, we should have preliminary answers in late June.
- The DORPANK study combining Ampligen and Dervalumab as therapy post-Pulverinox in metastatic pancreas cancer is proceeding according to schedule.
- As we recently reported, the first three patients of the three-in-three design have completed the safety evaluation, and the few adverse events observed were only grade one with no serious adverse events.
Bear points
- our G&A expenses were up from the same period last year.
- our G&A expenses were up from the same period last year.
- The costs, especially in this medical R&D space, have all increased over time.
Read full transcript analysis ›